We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+1.26%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$4.8B
AUM Growth
-$159M
Cap. Flow
-$187M
Cap. Flow %
-3.89%
Top 10 Hldgs %
18.32%
Holding
695
New
64
Increased
242
Reduced
263
Closed
62

Top Sells

Rank Stock Value
1
EWJ icon
iShares MSCI Japan ETF
EWJ
+$40.8M
2
INTU icon
Intuit
INTU
+$32.8M
3
META icon
Meta Platforms (Facebook)
META
+$30.3M
4
MA icon
Mastercard
MA
+$28.3M
5
NKE icon
Nike
NKE
+$25.9M

Sector Composition

Rank Sector Weight
1 Healthcare 29.43%
2 Financials 13.37%
3 Technology 9.86%
4 Consumer Discretionary 7.77%
5 Industrials 7.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KPTI icon
276
Karyopharm Therapeutics
KPTI
$168M
$3.62M 0.08%
8,867
-9,066
-51% -$3.92M
ONCE
277
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$3.62M 0.08%
60,000
+5,000
+9% +$331K
HUM icon
278
Humana
HUM
$46.7B
$3.53M 0.07%
18,458
-3,500
-16% -$650K
SU icon
279
Suncor Energy
SU
$77.7B
$3.49M 0.07%
126,523
-13,715
-10% -$414K
LRMR icon
280
Larimar Therapeutics
LRMR
$416M
$3.46M 0.07%
8,333
MRTX
281
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.46M 0.07%
110,000
-4,000
-4% -$118K
OVV icon
282
Ovintiv
OVV
$17.5B
$3.44M 0.07%
62,324
+15,949
+34% +$1.01M
BCE icon
283
BCE
BCE
$19.9B
$3.42M 0.07%
80,477
-13,526
-14% -$594K
PBYI icon
284
Puma Biotechnology
PBYI
$406M
$3.39M 0.07%
29,000
+12,000
+71% +$2.17M
TGT icon
285
Target
TGT
$62.1B
$3.38M 0.07%
41,420
+9,216
+29% +$746K
ACHN
286
DELISTED
Achillion Pharmaceuticals
ACHN
$3.37M 0.07%
380,000
+25,000
+7% +$236K
RTN
287
DELISTED
Raytheon Company
RTN
$3.32M 0.07%
34,691
-17,452
-33% -$1.83M
WMT icon
288
Walmart Inc
WMT
$871B
$3.31M 0.07%
140,187
+12,486
+10% +$318K
LNC icon
289
Lincoln National
LNC
$7.91B
$3.31M 0.07%
55,880
-164,413
-75% -$9.63M
BNS icon
290
Scotiabank
BNS
$106B
$3.3M 0.07%
66,876
+7,252
+12% +$370K
HALO icon
291
Halozyme
HALO
$9.72B
$3.23M 0.07%
143,000
-167,000
-54% -$2.94M
GTI
292
DELISTED
GRAFTECH INTERNATIONAL LTD
GTI
$3.22M 0.07%
+649,866
New +$3.08M
KMI icon
293
Kinder Morgan
KMI
$73.1B
$3.2M 0.07%
83,274
+25,644
+44% +$1.07M
PTCT icon
294
PTC Therapeutics
PTCT
$6.37B
$3.18M 0.07%
66,000
-31,000
-32% -$1.81M
RXDX
295
DELISTED
Ignyta, Inc.
RXDX
$3.17M 0.07%
+210,000
New +$2.54M
XLRN
296
DELISTED
Acceleron Pharma
XLRN
$3.16M 0.07%
100,000
+32,000
+47% +$1.03M
GGP
297
DELISTED
GGP Inc.
GGP
$3.16M 0.07%
+123,317
New +$3.44M
OREX
298
DELISTED
Orexigen Therapeutics, Inc.
OREX
$3.14M 0.07%
63,500
CMRX
299
DELISTED
Chimerix, Inc.
CMRX
$3.14M 0.07%
68,000
+3,000
+5% +$120K
BBD icon
300
Banco Bradesco
BBD
$38.1B
$3.11M 0.06%
721,947

Similar funds

Candriam SCA's Q2 2015 Portfolio in Review

As of Q2 2015, Candriam SCA held 695 positions worth $4.8B, down 3.2% from $4.96B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Candriam SCA withdrew a net $187M in Q2 2015, closing 62 positions and reducing 263 holdings. Its most notable exit was iShares MSCI Japan ETF, an estimated $40.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, up from 28% a quarter earlier, followed by Financials and Technology.

Against the trend, Candriam SCA opened a new position in American Airlines Group worth $11.6M.

  • Candriam SCA's largest Q2 2015 buy was American Airlines Group: 290,014 shares worth $11.6M.
  • Candriam SCA added most to Alphabet (Google) Class C in Q2 2015, an estimated $33.8M increase.
  • Candriam SCA's biggest Q2 2015 reduction was Intuit, cutting an estimated $32.8M.
  • Candriam SCA fully exited iShares MSCI Japan ETF in Q2 2015, selling an estimated $40.8M.
  • Candriam SCA's ten largest holdings make up 18% of its $4.8B portfolio in Q2 2015.
  • Candriam SCA opened 64 new positions and closed 62 in Q2 2015.
  • Candriam SCA's portfolio value fell 3.2% quarter-over-quarter to $4.8B.

Based on Candriam SCA's 13F filing for Q2 2015, filed 29 Jul 2015.